Funder: National Institutes of Health
Due Dates: June 6, 2023 | June 6, 2024 | June 6, 2025 | October 6, 2025 | December 9, 2025 (final closing)
Funding Amounts: Phase I: up to $295,924 total costs (6 months); Phase II: up to $1,972,828 total costs (2 years); higher budgets possible for approved waiver topics.
Summary: Supports U.S. small businesses developing novel extracellular vesicle-based therapeutic platforms for regenerative medicine, focusing on production, manufacturing, and use for tissue and organ repair.
Key Information: Clinical trials are not allowed; only U.S. small businesses are eligible.